PHI applies for listing on OTCQB in the United States
Phase Holographic Imaging (PHI) is pursuing a dual listing on the US-based OTCQB Venture Market (“OTCQB”) to provide US-based investors with the ability to invest in PHI. PHI aims to solidify further its presence in the major US market and within regenerative medicine, a rapidly evolving field, spearheaded by the United States globally. The application process has been initiated, and PHI expects to receive approval in the third quarter of 2024.PHI's CEO, Patrik Eschricht, comments: "We are excited about the potential of trading on the OTCQB as it offers our current and prospective